Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney shield: a simple care bundle may prevent organ failure after severe injury

NCT ID NCT06834633

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether a set of five kidney-protecting measures — given early to severe trauma patients identified as high-risk by a urine test — can reduce the chance of acute kidney injury. About 500 adults with severe injuries will be randomly assigned to receive either the bundle or standard care. The goal is to see if early, targeted action can prevent kidney damage within the first three days in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a bundle of five kidney-protecting measures (avoiding nephrotoxic drugs, optimizing blood flow, controlling blood sugar, detecting muscle breakdown, monitoring kidney function)
What this could lead to
If it works, this could give hospitals a simple, targeted way to prevent kidney failure in severely injured patients, potentially saving lives and reducing long-term complications.
What could go wrong
The bundle requires significant resources to implement fully, and earlier trials in other settings may not translate to trauma patients. The test used to identify high-risk patients is not perfect, so some may be misclassified.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 523 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (≥ 18 years) * Severe trauma patients (ISS score \> 15) admitted to a trauma center * Time between trauma and admission to trauma center \<6h * High risk of AKI: at least one NC score greater than 0.3 within 12 hours of admission to critical care (intensive care and continuous monitoring unit) * Affiliated with a social security scheme or beneficiary of a similar scheme * Consent signed by patient or close relative, or attestation signed by investigator in case of emergency Exclusion Criteria: * Adult under legal protection (guardianship, curators) * Persons deprived of their liberty by judicial or administrative decision * Patients taking part in other interventional research which may interfere with the research and which includes an exclusion period still in progress at the time of inclusion. * Pregnant or breast-feeding woman (diagnosis of pregnancy by plasma βHCG (Beta-Human Chorionic Gonadotropin) assay routinely performed as part of the blood test on admission to the outpatient department of a woman of childbearing age). * Patients with end-stage or severe chronic renal failure with Glomerular Filtration Rate (GFR) \< 30 milliliters/min/1.73m2 or chronic dialysis. * Anuric patients * Severe heart failure defined as Left Ventricular Ejection Fraction (LVEF) \<25%. * Patient moribund on admission with an estimated length of stay of less than 24 hours * Patient with AKI at time of randomization (developed prior to ICU admission or within the first 12 hours of ICU admission, before randomization).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Trauma; complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier universitaire Estaing, Service anesthésie-réanimation

    RECRUITING

    Clermont-Ferrand, 63100, France

  • Centre hospitaler Annecy Genevois, Service de réanimation

    RECRUITING

    Épagny, 74370, France

  • Centre hospitalier universitaire de Grenoble Alpes, Pôle anesthésie-réanimation

    RECRUITING

    La Tronche, 38700, France

  • Centre hospitalier universitaire de Saint Etienne, Hôpital Bellevue, Service anesthésie-réanimation

    RECRUITING

    Saint-Etienne, 42000, France

  • Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'anesthésie-réanimation

    RECRUITING

    Lyon, 69003, France

  • Hospices Civils de Lyon, Hôpital Lyon-Sud, Service d'anesthésie-réanimation

    RECRUITING

    Pierre-Bénite, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.